Comment on "Impact of UK Medical Eligibility Criteria implementation on prescribing of combined hormonal contraceptives'

被引：1
|
作者：
Holden, Sarah E. [1 ,2 ]
机构：
[1] Cardiff Univ, Sch Med, Dept Primary Care & Publ Hlth, Cardiff CF10 3AX, S Glam, Wales
[2] Cardiff MediCtr, Pharma Res Ctr, Cardiff, S Glam, Wales
来源：
JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE | 2013年 / 39卷 / 03期
关键词：
epidemiology; family planning service provision; general practice; hormonal contraception; oral contraceptives;
D O I：
10.1136/jfprhc-2013-100627
中图分类号：
D669 [社会生活与社会问题]; C913 [社会生活与社会问题];
学科分类号：
1204 ;
摘要：
引用
收藏
页码：229 / 230
页数：2
相关论文
共 48 条
  • [31] Implementation and perception of outpatient pharmacists prescribing hormonal contraceptives in North Carolina (Reprinted from J Am Pharm Assoc, vol 64, 102070, 2024)
    Martinez, Joseph T.
    Trotta, Katie
    Honeycutt, James P., III
    Herring, Charles
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2024, 64 (04)
  • [32] Barriers and facilitators to implementation of non-medical independent prescribing in primary care in the UK: a qualitative systematic review
    Edwards, Judith
    Coward, Melaine
    Carey, Nicola
    BMJ OPEN, 2022, 12 (06):
  • [33] Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case-control study and meta-analysis
    Fitzpatrick, Danielle
    Pirie, Kirstin
    Reeves, Gillian
    Green, Jane
    Beral, Valerie
    PLOS MEDICINE, 2023, 20 (03)
  • [34] Eligibility criteria of randomized controlled trials published in high-impact general medical journals - A systematic sampling review
    Van Spall, Harriette G. C.
    Toren, Andrew
    Kiss, Alex
    Fowler, Robert A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (11): : 1233 - 1240
  • [35] Do we Still Need Eligibility Criteria to Recommend PrEP? Impact of National Prescribing Requirements on Retention in Care and Sexually Transmitted Infections Acquisition
    Rossotti, Roberto
    Tavelli, Alessandro
    Calzavara, Daniele
    De Bona, Anna
    Muccini, Camilla
    Moschese, Davide
    Caruso, Enrico
    Soria, Alessandro
    Bossolasco, Simona
    Lapadula, Giuseppe
    Cernuschi, Massimo
    Monforte, Antonella d'Arminio
    AIDS AND BEHAVIOR, 2024, 28 (07) : 2258 - 2263
  • [36] Comment on 'Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism' Reply
    Terplan, Mishka
    Zuckerman, Diana
    JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2013, 39 (04): : 304 - 305
  • [37] Contraception in adolescents with anorexia nervosa. Is there evidence for a negative impact of combined hormonal contraceptives on bone mineral density and the course of the disease?
    Merki-Feld, Gabriele Susanne
    Bitzer, Johannes
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2020, 25 (03): : 213 - 220
  • [38] Impact of PSA implementation and combined radiation and hormonal therapy (RT plus HT) on outcome of prostate cancer patients
    Bellmunt, Joaquim
    Macia, Francesc
    Malmusi, Davide
    Llorente, Jose A.
    Carles, Joan
    Lloreta, Josep
    Foro, Palmira
    Gelabert, Antoni
    Albanell, Joan
    Castells, Xavier
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (16) : 2804 - 2809
  • [39] Update to CDC's US Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection
    Tepper, Naomi K.
    Krashin, Jamie W.
    Curtis, Kathryn M.
    Cox, Shanna
    Whiteman, Maura K.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2017, 66 (37): : 990 - 994
  • [40] Impact of EU risk assessment process and administrative regulations for manufacturers of combined hormonal contraceptive prescribing. An analysis of developments in Germany and the implications
    Krulichova, Iva Selke
    Selke, Gisbert W.
    Eichler, Uwe
    Lappe, Veronika
    Godman, Brian
    Schubert, Ingrid
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (04) : 697 - 704
12345